ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023 20 Dec 2022
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
The industry organisation states that unless the scheme is reviewed, the government’s Life Sciences Vision will be in jeopardy. The current agreement is set to end in December 2023.
Increased health needs, the effects of the COVID-19 pandemic, NHS demand and use of new medicines have driven up repayment rates ‘far beyond sustainable levels’, the ABPI points out.